{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:13:37Z","timestamp":1773422017311,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1016\/j.pnpbp.2006.10.007","type":"journal-article","created":{"date-parts":[[2006,11,29]],"date-time":"2006-11-29T16:30:32Z","timestamp":1164817832000},"page":"399-402","source":"Crossref","is-referenced-by-count":25,"title":["The effects of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity in schizophrenic patients: A double blind study"],"prefix":"10.1016","volume":"31","author":[{"given":"M.","family":"Jakovljevic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Pivac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Mihaljevic-Peles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mustapic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Relja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ljubicic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Marcinko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Muck-Seler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2006.10.007_bib1","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0893-133X(94)00129-N","article-title":"Radioreceptor binding profile of the atypical antipsychotic olanzapine","volume":"14","author":"Bymaster","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00213-005-0279-x","article-title":"The atypical antipsychotics olanzapine and quetiapine, but not haloperidol, reduce ACTH and cortisol secretion in healthy subjects","volume":"185","author":"Cohrs","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0169-328X(97)00144-7","article-title":"Modulation of basal ganglia neurotransmission by the classical antipsychotic fluphenazine is due in part to the blockade of dopamine D1-receptors","volume":"49","author":"Coirini","year":"1997","journal-title":"Mol Brain Res"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0278-5846(00)00176-7","article-title":"An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy","volume":"25","author":"Crocker","year":"2001","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib6","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0920-9964(98)00159-5","article-title":"Neuroleptic-induced hyperprolactinemia","volume":"35","author":"Dickson","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.pnpbp.2003.10.010","article-title":"Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia","volume":"28","author":"Dossenbach","year":"2004","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","article-title":"Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects","volume":"28","author":"Halbreich","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib9","first-page":"389","article-title":"Basal cortisol, dexamethasone suppression test and platelet 5-HT in recurrent (unipolar) major depression, schizophrenia and schizoaffective disorders","volume":"4","author":"Jakovljevic","year":"1991","journal-title":"Psychiatr Danub"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib10","doi-asserted-by":"crossref","first-page":"s397","DOI":"10.1016\/S0924-977X(01)00109-2","article-title":"Extrapyramidal side effects are unacceptable","volume":"11","author":"Kane","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/archpsyc.1994.03950100009002","article-title":"Effects of menstrual cycle an dependent variables in mood disorder research","volume":"51","author":"Leibenluft","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib13","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.psyneuen.2005.08.005","article-title":"Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine","volume":"31","author":"Mann","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s004060170049","article-title":"Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatemnt with clozapine, olanzapine, risperidone, sulpiride or haloperidol","volume":"251","author":"Markianos","year":"2001","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib15","first-page":"587","article-title":"VII: Effects of antipsychotic drugs on serotonin receptors","volume":"43","author":"Meltzer","year":"1991","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00023210-199402050-00006","article-title":"Newer and older antipsychotics. A comparative review of appropriate use","volume":"2","author":"Mortimer","year":"1994","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib17","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0006-3223(98)00174-7","article-title":"Platelet serotonin and plasma cortisol, and dexamethasone suppression test in schizophrenic patients","volume":"45","author":"Muck-Seler","year":"1999","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.psychres.2004.04.001","article-title":"Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women","volume":"127","author":"Muck-Seler","year":"2004","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0893-133X(96)00218-7","article-title":"A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine on healthy subjects","volume":"16","author":"Nyberg","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib20","doi-asserted-by":"crossref","first-page":"s67","DOI":"10.1016\/S0920-9964(98)00158-3","article-title":"Prolactin and antipsychotic medications: mechanism of action","volume":"35","author":"Petty","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib21","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.schres.2005.05.020","article-title":"Performance of diadochokinetic movements in schizophrenic patients","volume":"79","author":"Putzhammer","year":"2005","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib22","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/00002826-199619020-00003","article-title":"Quantifying rigidity with a new computerized elbow device","volume":"19","author":"Relja","year":"1996","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antypsychotic drugs to human brain receptors. Focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.psyneuen.2003.08.011","article-title":"Evidence of basal pituitary-adrenal overactivity in first episode, drug na\u00efve patients with schizophrenia","volume":"29","author":"Ryan","year":"2004","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib25","first-page":"233","article-title":"Aging and hypothalamic-pituitary-adrenal response to challenge in humans","volume":"15","author":"Seeman","year":"1994","journal-title":"Endocrinol Rev"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0306-4530(02)00109-9","article-title":"The second-generation \u2018atypical\u2019 antipsychotics: similar improved efficacy but different neuroendocrine side-effects","volume":"28","author":"Tandon","year":"2003","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.pnpbp.2006.10.007_bib27","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/0006-3223(91)90353-N","article-title":"Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome","volume":"29","author":"Tandon","year":"1991","journal-title":"Biol Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858460600385X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858460600385X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T02:56:09Z","timestamp":1547175369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027858460600385X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["S027858460600385X"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2006.10.007","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}